Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data readouts for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - The company is projected to generate revenue of RMB 1.30 billion in 2025, a 24% year-on-year increase, primarily from overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is forecasted to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is expected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - Revenue projections for 2026E are set at USD 85 million, with gross profit expected to be USD 33 million, maintaining a gross margin of 39.3% [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of registration studies for non-small cell lung cancer (NSCLC). Additionally, the confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are highlighted as key developments [6][12].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data releases for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - Revenue for 2025 is projected at RMB 130 million, a 24% year-on-year increase, primarily driven by overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is expected to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is projected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - The report provides updated revenue forecasts for 2026E at USD 85 million, with a gross profit of USD 33 million and a gross margin of 39.3%. The net loss for 2026E is projected at USD 353 million [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of a registrational study for non-small cell lung cancer (NSCLC). Additionally, confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are expected [6][12].

Group 1: WuXi Biologics (2269 HK) - Significant improvement in profit margins expected in 2025, driven by new technologies and CMO [1] - Revenue for 2025 projected at RMB 21.8 billion, a 17% year-on-year increase, with gross margin rising by 5.0 percentage points to 46.0% [1] - Free cash flow expected to grow over 70% to RMB 2.3 billion, with capital expenditures around RMB 7.1 billion [1][2] - Target price raised to HKD 35.80, maintaining a neutral rating [2] Group 2: Gensun Pharmaceuticals (2595 HK) - Revenue for 2025 expected to reach RMB 130 million, a 24% year-on-year increase, with adjusted losses narrowing by 9% to RMB 227 million [3] - Cash reserves at year-end projected to exceed RMB 2 billion, supporting R&D and operations for the next 2-3 years [3] - Anticipated significant sales growth in 2026 following the inclusion of Fluorouracil in the medical insurance directory [3] Group 3: Hesai Technology (2525 HK) - Revenue for Q4 2025 reached RMB 1 billion, a 39% year-on-year increase, with a shipment volume of 631,000 units, up 184.2% [9] - Management raised 2026 shipment guidance to 3-3.5 million units, previously set at 2-3 million [9] - 2025 GAAP net profit expected at RMB 440 million, with a non-GAAP net profit of RMB 550 million [9][10] Group 4: Xiaomi Group (1810 HK) - Q4 2025 total revenue increased by 7% year-on-year to RMB 116.9 billion, with a gross margin of 20.8% [12] - Adjusted net profit decreased by 24% to RMB 6.35 billion, facing storage cost pressures [12][13] - Continued investment in AI expected to reach RMB 16 billion in 2026, with a cumulative investment of RMB 60 billion over three years [13] Group 5: ZhongAn Online (6060 HK) - Net profit for 2025 expected to increase by over 80% to RMB 1.102 billion, with a 198.3% increase when excluding one-time impairment losses [14][15] - Health insurance premium income projected to grow by 20% annually over the next three years [15] - Target price maintained at HKD 23, corresponding to a 1.40x 2026 target P/B ratio [16] Group 6: Henderson Land Development (12 HK) - Revenue for 2025 increased by 1.9% to HKD 25.74 billion, with net profit declining by approximately 10.2% to HKD 5.65 billion [17] - Contract sales in Hong Kong expected to reach HKD 19.271 billion, a 71% year-on-year increase [17] - Target price maintained at HKD 32.68, reflecting a significant discount to net asset value [18]